Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MDS by standard criteria. Patients within each of the FAB diagnostic groups of RA, RARS, RAEB, RAEBt, and CMML are eligible. For patients with lower-risk MDS only: documented red blood cell dependence, defined as the inability to maintain a hematocrit of \> 25% without transfusion support.~* Adequate marrow iron stores~* In patients with serum erythropoietin less than 200 IU/mL at screening, failure to have responded to a 2 to 3 month trial of recombinant erythropoietin~* Serum creatinine or serum bilirubin \< 1.5 times the upper limit of normal; higher levels are acceptable if ALT levels \< 2 x upper limits of normal~* Women of childbearing potential must have a negative serum pregnancy test prior to azacitidine/treatment.~* Women of childbearing potential should be advised to avoid becoming pregnant and should be advised to not father a child while receiving treatment with azacitidine~* Age \> 18 years~Exclusion Criteria:~* Treatment with growth factors within the 30 days before first treatment with ATO/Azacitidine, except that patients with serum erythropoietin \< 200 IU/mL who failed to respond to a trial with EPO are not excluded regardless of the time since last EPO~* Treatment with cytotoxic or experimental agents within 30 days before first treatment with ATO/Azacitidine~* Absolute QT interval \> 460 msec in the presence of adequate serum potassium and magnesium values~* Active serious infections that are not controlled by antibiotics~* Pregnant or lactating women~* Inability or unwillingness to comply with the treatment protocol, follow-up, or research tests~* NYHA Class III or IV heart failure~* Poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): see description in intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).